A series of awards is given annually by the AACR the world's oldest and largest professional society representing cancer scientists from the United States and more than 60 other countries to honor world-class accomplishments in basic research, clinical care, therapeutics and prevention. Each recipient presents a lecture at the AACR Annual Meeting.
"We are privileged to acknowledge just a few of the extraordinary men and women who, over the years, have given us a clear understanding of how cancer evolves and of the signals that drive and nourish its growth and spread, and those who have improved patient care and preventive strategies," said Margaret Foti, Ph.D., M.D. (h.c.), AACR chief executive officer.
"This is an exciting time in cancer research, and the AACR award winners are among the leaders in this new era of discovery, therapeutics and treatment," she added.
Each award has its own selection committee composed of members of the AACR. Peers and colleagues nominate the award candidates.
This year's winners represent institutions in Boston, Mass.; Baltimore, Md.; La Jolla and Los Angeles, Calif.; Columbus, Ohio; Dallas, Texas ; and New York, N.Y.
Frederick W. Alt, Ph.D., investigator, Howard Hughes Medical Institute,
The Children's Hospital of Boston; senior investigator, CBR Institute for Biomedical Research; Charles A. Janeway professor of pediatrics and professor of genetics, Harvard Medical School, will receive the 44th AACR-G.H.A. Clowes Memorial Award for his major discoveries involving genomic stability and cancer. The AACR and Eli Lilly and Company established this award in 1961 to honor Clowes, a founding member of
Contact: Elizabeth Tait
American Association for Cancer Research